Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs

  • Eur J Pharmacol. 1998 May 29;350(1):87-91. doi: 10.1016/s0014-2999(98)00328-8.
K Sato  1 ,  T Kawasaki ,  N Hisamichi ,  Y Taniuchi ,  F Hirayama ,  H Koshio ,  M Ichihara ,  Y Matsumoto
Affiliations
  • 1. Institute for Drug Discovery Research, Yamanouchi Pharmaceutical, Tsukuba, Ibaraki, Japan. [email protected]
PMID: 9683019 DOI: 10.1016/s0014-2999(98)00328-8
Abstract

The antithrombotic effects of a novel Factor Xa Inhibitor, YM-60828 ([N-[4-[(1-acetimidoyl-4-piperidyl)oxy]phenyl]-N-[(7-amidino-2-nap hthyl)methyl]sulfamoyl]acetic acid dihydrochloride), in three thrombosis models in guinea pigs were studied in comparison with its effect on bleeding time. The antithrombotic effects of YM-60828 were most pronounced in the venous thrombosis and the arterio-venous shunt models but YM-60828 showed 10-fold weaker effects in the carotid thrombosis model. However, YM-60828 prolonged bleeding time at a much higher dose than that required in all thrombosis models. In conclusion, YM-60828 exerted its antithrombotic effects without prolonging bleeding time in all thrombosis models and may be of clinical value not only in venous thrombosis but also in arterial thrombosis.

Products